

# Accepted Manuscript

Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1  $\geq 50\%$  expression in lung adenocarcinoma

Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Meghan Shea, MD, Xiuning Le, MD, PhD, Mark S. Huberman, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

PII: S1556-0864(17)30014-X

DOI: [10.1016/j.jtho.2016.12.026](https://doi.org/10.1016/j.jtho.2016.12.026)

Reference: JTHO 481

To appear in: *Journal of Thoracic Oncology*

Received Date: 21 November 2016

Revised Date: 20 December 2016

Accepted Date: 29 December 2016

Please cite this article as: Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB, Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1  $\geq 50\%$  expression in lung adenocarcinoma, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2016.12.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1  $\geq 50\%$  expression in lung adenocarcinoma**

Deepa Rangachari, MD<sup>1^</sup>; Paul A. VanderLaan, MD, PhD<sup>2^</sup>; Meghan Shea, MD<sup>1</sup>; Xiuning Le, MD, PhD<sup>1</sup>; Mark S. Huberman, MD<sup>1</sup>; Susumu S. Kobayashi, MD, PhD<sup>1</sup>; Daniel B. Costa, MD, PhD<sup>1\*</sup>

<sup>1</sup> Department of Medicine, <sup>2</sup> Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

^ these authors contributed equally

*Correspondence to:*

\*Daniel B. Costa, MD, PhD - Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Av., Boston, MA 02215  
Phone: 617-667-9236  
Fax: 617-975-5665  
Emails: [dbcosta@bidmc.harvard.edu](mailto:dbcosta@bidmc.harvard.edu)

*Running Title:* PD-L1 IHC and lack of overlap with driver oncogene mutations

*Manuscript type:* Brief Report

*Keywords:* lung cancer; adenocarcinoma; PD-L1; PD-1; pembrolizumab; EGFR; ALK; ROS1; kinase inhibitor; immune checkpoint inhibitor

*Funding/Grant Support:* This work was funded in part through an American Cancer Society grant RSG 11-186 (DBC), National Cancer Institute grants P50CA090578 (DBC), R01CA169259 (SSK) and R21CA17830 (SSK), and internal donations to Beth Israel Deaconess Medical Center.

*Conflict of interest:* DBC has received consulting fees and honoraria from Pfizer, Boehringer Ingelheim and Ariad pharmaceuticals; outside the submitted work. PAV has received consulting fees from Gala Therapeutics; outside the submitted work. No other conflict of interest is stated.

Download English Version:

<https://daneshyari.com/en/article/5701571>

Download Persian Version:

<https://daneshyari.com/article/5701571>

[Daneshyari.com](https://daneshyari.com)